Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25217051 | 0.92 | CYP19A1 (0.58) | EPHX2CYP19A1HTTHRH4HRH3 | |
| SCHEMBL12985578 | 0.85 | SMYD3 (0.50) | EPHX2CYP19A1IDO1NTRK1HRH4 | |
| SCHEMBL21653424 | 0.82 | EPHX2 (0.39) | EPHX2CYP19A1IDO1HTTNTRK1 | |
| SCHEMBL26947314 | 0.79 | CYP19A1 (0.55) | CYP19A1IDO1NTRK1HRH4HRH3 | |
| SCHEMBL31695215 | 0.79 | ACACB (0.46) | — | |
| SCHEMBL13172338 | 0.79 | MAPK1 (0.43) | CYP19A1IDO1GAA | |
| SCHEMBL26941019 | 0.74 | CYP19A1 (0.50) | CYP19A1IDO1NTRK1HRH4HRH3 | |
| SCHEMBL28759020 | 0.73 | CYP4F2 (0.43) | HTTGAA | |
| SCHEMBL12984289 | 0.72 | NPC1 (0.50) | EPHX2HTTNTRK1GAA | |
| SCHEMBL879385 | 0.72 | ICMT (0.40) | CYP19A1IDO1HRH4HRH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110546147-B | Phenoxyquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3615526-B1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-07-06 | — | — | US | disclosed |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA UK LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| EP-3615526-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110546147-A | Phenoxyquinazoline compounds and their use in the treatment of cancer | ASTRAZENECA AB | 2019-12-06 | — | — | CN | disclosed |
| WO-2018197643-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | WO | disclosed |
| EP-2694509-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | PFIZER LTD (GB) | 2016-05-18 | — | — | EP | disclosed |
| EP-2694509-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | PFIZER LTD (GB) | 2016-05-18 | — | — | EP | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014053967-A1 | PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014053968-A1 | PYRROLO[3,2-C]PYRIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| CN-103534257-A | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases | PFIZER | 2014-01-22 | — | — | CN | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | KIT, ABL1, RB1 | EPHX2 2918/4885CYP19A1 315/4885IDO1 2840/4885 |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, ABL1, RB1 | EPHX2 2918/4885CYP19A1 315/4885IDO1 2840/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | EPHX2 4546/4885CYP19A1 3762/4885IDO1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.